Ferring appoints Mirjam Mol-Arts to Executive Committee
Saint-Prex, Switzerland – 22 July, 2020 – Ferring Pharmaceuticals announced today that Mirjam Mol-Arts, previously Senior Vice President, Global Development, has been appointed to the position of Executive Vice President, Chief Science Officer and Chief Medical Officer. Per Falk, previously Chief Science Officer and President of the Executive Committee, will now focus exclusively on his role as President, leading the Executive Committee and Ferring into the company’s next phase of sustainable growth.
Since joining Ferring in 2018, Mirjam has had a major impact on Ferring’s R&D organisation, applying her knowledge and experience to strengthen the organisation’s capabilities and focus on patient centricity. Mirjam is a medical doctor with over 30 years’ experience in senior leadership roles spanning medical, research and development at MSD, Schering Plough, Organon and Solvay. Before joining Ferring, she was CEO of a newly formed science park with a focus on pharmaceutical innovation in the Netherlands.
The combined role of CSO and CMO will enable Ferring’s R&D and Medical organisations to work even more closely together, ensuring that the patient perspective drives each stage of the development journey.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.